Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Barry R. Davies(AstraZeneca (United Kingdom)), Martin Pass(AstraZeneca (United Kingdom))

Molecular Cancer Therapeutics

February 1, 2012

10.1158/1535-7163.mct-11-0824-t

Cited by 460

Related Papers

No related papers found

Powered by citation graph analysis